ACTO Technologies, a Toronto-based life sciences software company, has launched a suite of AI tools called SuperAgents, designed to automate tasks and provide real-time support for customer-facing workers in the pharmaceutical and medical device industries.
The product is built around individual job roles rather than isolated workflows, with the goal of helping sales representatives, medical staff, and other field professionals spend less time searching for information and more time working with health-care providers.
Lisa Dreher, director of national sales training at Currax Pharmaceuticals, an early adopter of the technology, described the impact on her field team.
“With ACTO SuperAgents, our field sales teams get instant access to critical information — from disease state science to compliance policies — without searching across systems. What once took hours now takes seconds, keeping reps focused in the field. We’ve accelerated time to field readiness, improved productivity and retention, and boosted confidence in HCP interactions. The feedback from our pilot was immediate — teams called it a game-changer before full rollout.”
How the system works
Each SuperAgent is configured for a specific role, such as sales, medical affairs, marketing, learning and development, patient services, or market access. The company says the agents are built using existing job descriptions as a starting point.
ACTO says the system is designed around four pillars: context awareness of how an individual works, integration with existing enterprise software, compliance and governance controls including audit trails, and a design philosophy intended to support workers rather than replace them.
The platform includes what ACTO describes as “empathetic AI,” which the company says allows the system to adapt to individual working patterns over time.
Executive outlook
Parth Khanna, chief executive officer of ACTO, framed the launch as an extension of the company’s existing work in training and coaching for life sciences organizations.
“We’re at a pivotal moment in technological innovation. AI is already transforming drug discovery — cutting years from development timelines and accelerating the delivery of new therapies to market. Our goal is to bring that same velocity to the post-approval phase, equipping customer-facing teams with role-based SuperAgents that automate workflows and free up more time to engage with HCPs — ultimately helping get therapies to the patients waiting in need.”
ACTO says it currently works with 14 of the top 50 pharmaceutical companies, as well as biotechnology and medical technology organizations. The company says the SuperAgents platform is validated to U.S. Food and Drug Administration (FDA) Part 11 standards and holds SOC 2 Type II certification, both of which relate to data integrity and security requirements common in regulated industries.
